Not available
Quote | Cerecor Inc. (NASDAQ:CERC)
Last: | $2.93 |
---|---|
Change Percent: | -1.68% |
Open: | $2.98 |
Close: | $2.93 |
High: | $2.98 |
Low: | $2.9 |
Volume: | 266,862 |
Last Trade Date Time: | 08/25/2021 04:41:35 am |
News | Cerecor Inc. (NASDAQ:CERC)
WAYNE, Pa. and ROCKVILLE, Md., July 16, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced that Mittie Doyle, MD, FACR has joined the Company as its Chief Medical Officer. “We are thrilled to have Mittie join and grow our leadership team at an exciting...
Following FDA review, Avalo’s IND application for AVTX-009 is active allowing Avalo to proceed with its Phase 2 trial (LOTUS) to evaluate the efficacy and safety of AVTX-009 in patients with hidradenitis suppurativa WAYNE, Pa. and ROCKVILLE, Md., July 09, 2024 (GLOBE NEWSWIRE) -- Ava...
Message Board Posts | Cerecor Inc. (NASDAQ:CERC)
Subject | By | Source | When |
---|---|---|---|
New board is: https://investorshub.advfn.com/Avalo-Therapeutics-AVTX-40053/ | AliasUser1 | investorshub | 09/14/2021 10:00:46 PM |
$cerc Cerecor wins Fast Track Designation https://www.biospace.com/article/2021- | frankkruemmel | investorshub | 05/11/2021 4:41:12 PM |
And up 25% this morning | JohnLocke101 | investorshub | 05/11/2021 1:43:22 PM |
Biggest negative operating margin ever seen -706.02%, book | make it happen | investorshub | 05/11/2021 1:28:10 PM |
https://www.marketwatch.com/story/cerecors-investigational-covid-19-therapy-gets | frankkruemmel | investorshub | 05/11/2021 1:13:09 PM |
News, Short Squeeze, Breakout and More Instantly...
Cerecor Inc. Company Name:
CERC Stock Symbol:
NASDAQ Market:
WAYNE, Pa. and ROCKVILLE, Md., July 16, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced that Mittie Doyle, MD, FACR has joined the Company as its Chief Medical Officer. “We are thrilled to have Mittie join and grow our leadership team at an exciting...
Following FDA review, Avalo’s IND application for AVTX-009 is active allowing Avalo to proceed with its Phase 2 trial (LOTUS) to evaluate the efficacy and safety of AVTX-009 in patients with hidradenitis suppurativa WAYNE, Pa. and ROCKVILLE, Md., July 09, 2024 (GLOBE NEWSWIRE) -- Ava...
WAYNE, Pa. and ROCKVILLE, Md., June 17, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board, will present on the Novel Immunological Mechanisms for Dermatological Disorders Panel being held at...